Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1991 1
1992 1
1993 2
1994 5
1995 3
1996 3
1997 9
1998 4
1999 9
2000 20
2001 27
2002 38
2003 32
2004 20
2005 14
2006 18
2007 21
2008 24
2009 20
2010 20
2011 28
2012 31
2013 33
2014 31
2015 33
2016 32
2017 28
2018 28
2019 20
2020 29
2021 23
2022 18
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

574 results

Results by year

Filters applied: . Clear all
Page 1
[Immunogenicity of biosimilars].
van Aerts LA, Franken AA, Leufkens HG. van Aerts LA, et al. Among authors: leufkens hg. Ned Tijdschr Geneeskd. 2016;160:D888. Ned Tijdschr Geneeskd. 2016. PMID: 28000573 Review. Dutch.
Emergent treatments for β-thalassemia and orphan drug legislations.
Costa E, Cappellini MD, Rivella S, Chilin A, Alessi E, Riccaboni M, Leufkens HGM, Luzzatto L. Costa E, et al. Among authors: leufkens hgm. Drug Discov Today. 2022 Nov;27(11):103342. doi: 10.1016/j.drudis.2022.103342. Epub 2022 Sep 1. Drug Discov Today. 2022. PMID: 36058507 Free article. Review.
Medicine shortages: impact behind numbers.
Postma DJ, Notenboom K, De Smet PAGM, Leufkens HGM, Mantel-Teeuwisse AK. Postma DJ, et al. Among authors: leufkens hgm. J Pharm Policy Pract. 2023 Mar 14;16(1):44. doi: 10.1186/s40545-023-00548-x. J Pharm Policy Pract. 2023. PMID: 36918981 Free PMC article.
Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.
Tetteh RA, Yankey BA, Nartey ET, Lartey M, Leufkens HG, Dodoo AN. Tetteh RA, et al. Among authors: leufkens hg. Drug Saf. 2017 Apr;40(4):273-283. doi: 10.1007/s40264-017-0505-6. Drug Saf. 2017. PMID: 28130774 Free PMC article. Review.
Four scenarios for the future of medicines and social policy in 2030.
Leufkens HG, Kusynová Z, Aitken M, Hoekman J, Stolk P, Klein K, Mantel-Teeuwisse AK. Leufkens HG, et al. Drug Discov Today. 2022 Aug;27(8):2252-2260. doi: 10.1016/j.drudis.2022.03.018. Epub 2022 Mar 29. Drug Discov Today. 2022. PMID: 35364271 Free article. Review.
Factors related to drug approvals: predictors of outcome?
Liberti L, Breckenridge A, Hoekman J, McAuslane N, Stolk P, Leufkens H. Liberti L, et al. Among authors: leufkens h. Drug Discov Today. 2017 Jun;22(6):937-946. doi: 10.1016/j.drudis.2017.03.003. Epub 2017 Mar 10. Drug Discov Today. 2017. PMID: 28288783 Review.
The interface between pharmacoepidemiology and pharmacogenetics.
Maitland-van der Zee AH, de Boer A, Leufkens HG. Maitland-van der Zee AH, et al. Among authors: leufkens hg. Eur J Pharmacol. 2000 Dec 27;410(2-3):121-130. doi: 10.1016/s0014-2999(00)00810-4. Eur J Pharmacol. 2000. PMID: 11134664 Review.
Traceability of biologicals: present challenges in pharmacovigilance.
Vermeer NS, Spierings I, Mantel-Teeuwisse AK, Straus SM, Giezen TJ, Leufkens HG, Egberts TC, De Bruin ML. Vermeer NS, et al. Among authors: leufkens hg. Expert Opin Drug Saf. 2015 Jan;14(1):63-72. doi: 10.1517/14740338.2015.972362. Epub 2014 Nov 5. Expert Opin Drug Saf. 2015. PMID: 25369769 Review.
574 results